Scintillam Nutrapeutics Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 3 Year, 3 Days
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.20 M
About Scintillam Nutrapeutics
Scintillam Nutrapeutics Private Limited (SNPL) is a Private Limited Indian Non-Government Company incorporated in India on 25 February 2022 (Three years 3 days old ). Its registered office is in North West Delhi, Delhi, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.20 M.
Venkatesh Karthikeyan, Alok Sharma, and Pinka Bhattacharjee serve as directors at the Company.
Company Details
- Location
North West Delhi, Delhi, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24299DL2022PTC394344
- Company No.
394344
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
25 Feb 2022
- Date of AGM
30 Dec 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Pharma
Who are the key members and board of directors at Scintillam Nutrapeutics?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Venkatesh Karthikeyan  | Director | 27-Jun-2022 | Current |
| Alok Sharma | Director | 25-Feb-2022 | Current |
| Pinka Bhattacharjee | Director | 25-Feb-2022 | Current |
Financial Performance of Scintillam Nutrapeutics.
Scintillam Nutrapeutics Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Scintillam Nutrapeutics?
Unlock access to Scintillam Nutrapeutics's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
- Scintillam Solutions (Opc) Private Limited
Venkatesh Karthikeyan is a mutual person
Charges (Loans)
Open Charges
₹1.20 M
Satisfied Charges
₹0
Charges Breakdown by Lending Institutions
- Others : 0.12 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 10 May 2024 | Others | ₹1.20 M | Open |
How Many Employees Work at Scintillam Nutrapeutics?
Scintillam Nutrapeutics has a workforce of 0 employees as of Mar 29, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Scintillam Nutrapeutics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Scintillam Nutrapeutics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.